[Impact of new therapeutic products for the treatment of chronic obstructive pulmonary disease and asthma in primary care in Madrid between 1996 and 2005]. / Impacto de las novedades terapéuticas para el tratamiento de la enfermedad pulmonar obstructiva crónica y el asma en atención primaria de Madrid, entre 1996 y 2005.

OBJECTIVES: To analyze the trend of use of new drugs for the treatment of chronic obstructive pulmonary disease in primary care of Madrid (Spain) between 1996 and 2005, and to evaluate its impact in terms of supply, use and costs. METHODS: Drug utilization study of new products of the R03 group (Anatomical Therapeutic Chemical Classificaction System: drugs for obstructive airway diseases) prescribed by doctors of primary care of Madrid, during 1996 and 2005. Information on drug utilization and cost was obtained from the prescription database. Date was expressed in daily doses defined by 1,000 inhabitants and day. RESULTS: The supply experiences few quantitative variations although of great qualitative interest, when disappearing drugs without therapeutic utility and commercializing 6 therapeutic new products. In 2005, the use of the 6 new products generates 28.03% of the total of the consumption and 79% of the costs. The new drugs of greater impact are salmeterol/fluticasone and tiotropio. CONCLUSIONS: The supply of medicines qualitatively improves when disappearing drugs without therapeutic utility. The consumption of therapeutic new products has a great impact on the total consumption of the R03 group and, mainly, in the costs by its elevated price, in spite of contributing only limited therapeutic advantages. The new drugs have been gotten up at great speed to the prescription.

Enfermedad de Kawasaki en un lactante de dos meses / Kawasaki disease in a two months old infant

La enfermedad de Kawasaki (EK) es un síndrome vasculítico multisistémico febril agudo, autolimitado, de etiología incierta. Se manifiesta frecuentemente en niños menores de cinco años de edad, siendo poco común en menores de tres meses. El diagnóstico se establece a partir de un cuadro clínico compatible, asociado a alteraciones sugestivas en los exámenes complementarios. El tratamiento consiste en la administración de gammaglobulina hiperinmune y ácido acetilsalicílico dentro de los primeros diez días del inicio de la sintomatología. Se presenta una paciente de dos meses de edad que cumple todos los criterios diagnósticos de la enfermedad. El tratamiento se realiza en forma precoz, siendo su evolución favorable, sin secuelas cardiovasculares hasta el momento actual. Si bien esta enfermedad es poco frecuente, se destaca la importancia de pensar en ella, aún en lactantes pequeños, dado que la instauración temprana del tratamiento puede disminuir la incidencia de aneurismas coronarios.